

performed in 10 mM phosphate buffer saline, pH 7.4 (containing 0.02% Tween 80), and the release properties were compared with microspheres containing native peptides. The PLGA microspheres containing native peptides demonstrated an initial rapid release in the early stage of incubation, whereas the microspheres containing PEGylated peptides rarely showed initial burst release and, instead, the release began at day 15. The release profile of PEGylated peptides from the microsphere exhibited a near zero order kinetic behavior during 20 days. Consequently, the PEG conjugation of peptide was demonstrated to be the potential way to add desirable function, (1) to minimize initial burst release and (2) to control the release rate of drug from microspheres, to the microsphere for controlled drug delivery.

[PE1-29] [10/19/2000 (Thr) 15:00 – 16:00 / [Hall B]]

Polyethylene glycol (PEG)-modified Glucagon-like Peptide-1 (GLP-1) which have increased metabolic stability and improved biological activity

Jung YH^o, Lee IB, Na DH, Park MO, Lee KC

Drug Targeting Laboratory, College of Pharmacy, SungKyunKwan University

Glucagon-like Peptide-1 (GLP-1) has great potential in diabetes therapy due to its glucose-dependent stimulation of insulin secretion, but this has been limited due to its rapid degradation, primarily by dipeptidyl peptidase IV (DPP IV). To overcome this problem, GLP-1 was modified with polyethylene glycol (PEG) and the metabolic stability and biological activity was tested in vitro and in vivo. Mono-PEGylated GLP-1 was separated by size-exclusion chromatography (SEC) and characterized by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry. Incubation of GLP-1 with DPP IV resulted in degradation of native GLP-1 (7-36) amide to GLP-1 (9-36) amide, while mono-PEG-GLP-1 was resistant to DPP IV degradation. The in vitro and in vivo biological activities were investigated by measuring cyclic AMP production in RINm5F cells and blood glucose levels lowered after intravenous administration to rats, respectively. The results of the experiments demonstrate that modification of GLP-1 with PEG increased the plasma stability against DPP IV without impairing significantly its insulinotropic activity. This may indicate that this modification can improve the potential of GLP-1 in the treatment of type-II diabetes.

[PE1-30] [10/19/2000 (Thr) 15:00 – 16:00 / [Hall B]]

Characterization of Carbohydrate-Directed PEGylation of Ricin A Chain

Yoon YS^o, Na DH, Park MO, Lee KC

Drug Targeting Laboratory, College of Pharmacy, SungKyunKwan University

Ricin A chain, toxic subunit of plant toxin ricin from *Ricinus Communis*, has been modified by carbohydrate-directed PEGylation to prolong circulating half-life. The site-directed PEGylation of the carbohydrate was compared to non-specific PEGylation of amino residues of RTA. The carbohydrate of RTA was oxidized with sodium m-periodate and modified with monomethoxy polyethylene glycol-hydrazide (MPEG-HZ, MW 5,000). PEGylation of amino group of RTA was performed with mPEG-succinimydyl propionate (MPEG-SPA, MW 5,000). The PEG-modified RTAs were purified by size-exclusion HPLC and characterized by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). RTA, RTA-MPEG-HZ and RTA-MPEG-SPA were radioiodinated by chloramine T-method and injected i.v. to rats. Blood clearance and tissue distribution were investigated. The systemic clearance of the RTA-MPEG-HZ and RTA-MPEG-SPA were reduced 64.8% and 34.1%, respectively, compared to native RTA. It was observed that RTA-MPEG-HZ was accumulated in the liver less than the RTA-MPEG-SPA and native RTA. The liver uptake of the RTA-MPEG-HZ and RTA-MPEG-SPA were reduced 62.4% and 32.6%, respectively, compared to native RTA. The kidney uptake of both RTA-MPEG-HZ and RTA-MPEG-SPA was also lower than that of native RTA. The site-directed PEGylation of the